Wedge Capital Management L L P NC Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Wedge Capital Management L L P NC increased its stake in Supernus Pharmaceuticals by 9.8%, owning 73,900 shares valued at approximately $2.33 million.
• Several hedge funds also boosted their positions in Supernus Pharmaceuticals, with ProShare Advisors LLC increasing their stake by 29.0% during the fourth quarter.
• Supernus Pharmaceuticals has received positive ratings from analysts, with Cantor Fitzgerald raising its price target from $42.00 to $46.00 and Zacks upgrading the stock to a "strong-buy."

Wedge Capital Management L L P NC raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,900 shares of the specialty pharmaceutical company's stock after acquiring an additional 6,614 shares during the period. Wedge Capital Management L L P NC owned approximately 0.13% of Supernus Pharmaceuticals worth $2,329,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Supernus Pharmaceuticals by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after buying an additional 1,083 shares during the period. Nuveen Asset Management LLC raised its position in Supernus Pharmaceuticals by 0.7% during the 4th quarter. Nuveen Asset Management LLC now owns 134,127 shares of the specialty pharmaceutical company's stock worth $4,850,000 after buying an additional 903 shares during the last quarter. Quantinno Capital Management LP grew its stake in Supernus Pharmaceuticals by 11.5% in the 4th quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after acquiring an additional 864 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Supernus Pharmaceuticals by 29.0% during the 4th quarter. ProShare Advisors LLC now owns 17,839 shares of the specialty pharmaceutical company's stock worth $645,000 after acquiring an additional 4,008 shares during the period. Finally, Two Sigma Advisers LP raised its stake in shares of Supernus Pharmaceuticals by 14.7% during the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after purchasing an additional 1,000 shares during the period.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $46.04 on Monday. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $46.78. The firm has a market capitalization of $2.58 billion, a PE ratio of 40.03 and a beta of 0.79. The company's fifty day moving average price is $40.67 and its 200-day moving average price is $35.08.

Insiders Place Their Bets

In related news, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares of the company's stock, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of Supernus Pharmaceuticals stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares in the company, valued at $55,434.54. This represents a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 246,506 shares of company stock worth $10,696,144. 8.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SUPN shares. Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Piper Sandler increased their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a report on Friday, August 29th. Zacks Research raised Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. Finally, Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $43.00.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.